financetom
Business
financetom
/
Business
/
Architectural products firm Apogee Q2 net sales beat estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Architectural products firm Apogee Q2 net sales beat estimates
Oct 9, 2025 3:43 PM

Overview

* Apogee Enterprises Inc ( APOG ) Q2 net sales rise 4.6% to $358 mln, beating analyst expectations

* Adjusted EPS for Q2 beats analyst expectations at $0.98

* Company's Q2 adjusted EBITDA margin fell due to lower prices and unfavorable mix

Outlook

* Company expects fiscal 2026 net sales of $1.39 bln to $1.42 bln

* Apogee forecasts fiscal 2026 diluted EPS of $2.79 to $3.19

* Company projects fiscal 2026 adjusted diluted EPS of $3.60 to $3.90

Result Drivers

* INORGANIC GROWTH - Acquisition of UW Solutions contributed $24.9 mln to net sales, boosting Performance Surfaces segment

* HIGHER COSTS - Gross margin decreased due to higher material, tariff, and health insurance costs, partially offset by lower incentive compensation expense

* ARCHITECTURAL SERVICES - Increased volume in Architectural Services drove segment sales growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Sales Beat $358.19 $351.70

mln mln (4

Analysts

)

Q2 Beat $0.98 $0.84 (4

Adjusted Analysts

EPS )

Q2 EPS $1.10

Q2 Net $23.64

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the construction supplies & fixtures peer group is "buy"

* Wall Street's median 12-month price target for Apogee Enterprises Inc ( APOG ) is $51.75, about 16.3% above its October 8 closing price of $43.32

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Albany International to Consolidate Italy Manufacturing Operations
Albany International to Consolidate Italy Manufacturing Operations
Feb 14, 2025
08:05 AM EST, 02/14/2025 (MT Newswires) -- Albany International's ( AIN ) Albany International Italia affiliate said Friday that it will begin consultations with employee representatives about its decision to discontinue manufacturing operations at a facility in Ballo, Italy. The company said it plans to relocate operations to a Merone, Italy facility owned by Industrie Tessili Bresciane, another Albany International...
Canada Has to Tackle Its
Canada Has to Tackle Its "Excessive" Regulations, Says National Bank
Feb 14, 2025
08:05 AM EST, 02/14/2025 (MT Newswires) -- The United States President recently quipped that tariff is the most beautiful word in the dictionary, noted National Bank of Canada. For a small, trade-dependent economy like Canada -- where the U.S. is its largest partner -- this is deeply troubling. said the bank. As concerns about the U.S.'s trade strategy persist, this...
Upstart Holdings Files Mixed Securities Shelf
Upstart Holdings Files Mixed Securities Shelf
Feb 14, 2025
08:05 AM EST, 02/14/2025 (MT Newswires) -- Upstart Holdings ( UPST ) filed Friday a shelf registration statement with the US Securities and Exchange Commission covering the potential sale of an unspecified number of securities. The company said it may issue securities from time to time, including common stock, preferred stock, depositary shares, debt securities, warrants, subscription rights, purchase contracts,...
Moderna Struggles With Declining Q4 COVID Vaccine Sales, Stock Slides
Moderna Struggles With Declining Q4 COVID Vaccine Sales, Stock Slides
Feb 14, 2025
On Friday, Moderna Inc. ( MRNA )  reported a fourth-quarter EPS loss of $(2.91), missing the consensus of $(2.62), a turnaround from EPS income of $0.55 a year ago. The COVID-19 vaccine maker reported quarterly sales of $966 million, down from $2.81 billion a year ago, beating the consensus of $942.8 million. Net product sales for the fourth quarter of 2024 were...
Copyright 2023-2026 - www.financetom.com All Rights Reserved